Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

Investigational new drugs·2026

Same author

A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.

Liver cancer·2026

Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Journal for immunotherapy of cancer·2025

Same author

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

Journal of hematology & oncology·2025

Same author

Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.

JAMA network open·2025

Search research articles

Related Experiment Video

Updated: Mar 22, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Programming the immune checkpoint to treat hematologic malignancies.

Eric Vick¹, Daruka Mahadevan²

¹a Department of Hematology and Oncology , University of Tennessee Health Science Center/West Cancer Center , Memphis , TN , USA.

Expert Opinion on Investigational Drugs

|April 13, 2016

Summary

Immune checkpoint inhibitors targeting CTLA-4 and PD-1 show promise for hematologic malignancies. These therapies harness the immune system to fight cancer, offering new treatment options with manageable side effects.

Keywords:

CTLA-4 Hematologic malignancy PD-1 PD-L1 immune checkpoint inhibitors and activators immune related adverse events leukemia lymphoma multiple myeloma myelodysplastic syndromes

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Mar 22, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Area of Science:

Oncology
Immunology
Hematology

Background:

Hematologic malignancies exploit immune suppressive pathways like CTLA-4 and PD-1 to evade the immune system.
Monoclonal antibodies targeting immune checkpoints demonstrate efficacy in treating various relapsed/refractory lymphomas and leukemias.
PD-L1 expression on tumor cells and the tumor microenvironment (TME) is crucial for anti-PD-1 therapy success.

Purpose of the Study:

To review the development of immune checkpoint inhibitors and activators for hematologic malignancies.
To explore how these agents can reprogram the immune response against cancer.
To highlight the potential for curative treatment regimens.

Main Methods:

Review of current literature on immune checkpoint inhibitors and activators.
Discussion of mechanisms of action in hematologic malignancies.
Analysis of therapeutic potential and clinical efficacy.

Main Results:

Immune checkpoint inhibitors are effective in treating specific hematologic cancers.
Therapies targeting PD-1 rely on PD-L1 expression for efficacy.
Adverse events can mimic autoimmune conditions but are generally manageable.

Conclusions:

Immune checkpoint targeting agents offer a novel therapeutic strategy to enhance immune responses against hematologic malignancies.
These therapies present an opportunity for developing treatments with improved clinical efficacy.
Management of immune-related adverse events is essential for successful treatment.